dc.contributor.author | Shankaran, V | |
dc.contributor.author | Xiao, H | |
dc.contributor.author | Bertwistle, D | |
dc.contributor.author | Zhang, Y | |
dc.contributor.author | You, M | |
dc.contributor.author | Abraham, P | |
dc.contributor.author | Chau, I | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-09-13T08:59:48Z | |
dc.date.available | 2022-09-13T08:59:48Z | |
dc.date.issued | 2020-11-26 | |
dc.identifier | 10.1007/s12325-020-01567-9 | |
dc.identifier.citation | Advances in Therapy, 2020, 38 (1), pp. 707 - 720 | en_US |
dc.identifier.issn | 0741-238X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5444 | |
dc.identifier.eissn | 1865-8652 | |
dc.identifier.eissn | 1865-8652 | |
dc.identifier.doi | 10.1007/s12325-020-01567-9 | |
dc.description.abstract | INTRODUCTION: Management of locally advanced, unresectable, or metastatic (adv/met) esophageal adenocarcinoma (EAC) follows clinical guidance for gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, evidence for these guidelines is based largely on patients with adv/met GC/GEJC, and generally excludes patients with EAC. It is currently unclear whether patients with adv/met GC/GEJC and adv/met EAC have similar demographics and clinical outcomes in real-world practice. METHODS: Adult patients diagnosed with adv/met GC/GEJC and adv/met EAC between January 1, 2011 and November 30, 2018 were identified (Flatiron Health database); patients with confirmed human epidermal growth factor receptor 2 (HER2)-positive tumors were excluded, and index was date of adv/met diagnosis. Median overall survival (OS) from start of first-line therapy until death/censoring was estimated by the Kaplan-Meier method. Multivariable analysis (Cox proportional hazards) was conducted to identify factors associated with OS. RESULTS: In total, 3052 patients were identified (adv/met GC/GEJC, n = 2083; adv/met EAC, n = 969). Patients with EAC were more likely to be male, have a history of smoking, have a higher body weight and body mass index, and were less likely to be Hispanic/Latino or Medicaid enrollees than patients with GC/GEJC. A similar proportion of patients with adv/met GC/GEJC (75%; n = 2326) and adv/met EAC (77%; n = 1573) received first-line therapy. Fluoropyrimidine plus platinum combinations were the most frequent first-line regimen in both groups (36%). Median OS was similar for patients with adv/met GC/GEJC and adv/met EAC (9.7 vs. 9.1 months, respectively; hazard ratio [95% confidence interval] 0.96 [0.87-1.06]; p = 0.4320). CONCLUSION: Despite minor differences in baseline demographics, clinical outcomes for patients with adv/met GC/GEJC and EAC are similar. This supports the inclusion of patients with adv/met EAC in clinical trials assessing adv/med GC/GEJC. | |
dc.format | Print-Electronic | |
dc.format.extent | 707 - 720 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | SPRINGER | en_US |
dc.relation.ispartof | Advances in Therapy | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Esophageal adenocarcinoma | |
dc.subject | Gastric cancer | |
dc.subject | Gastroesophageal junction cancer | |
dc.subject | Adenocarcinoma | |
dc.subject | Adult | |
dc.subject | Esophageal Neoplasms | |
dc.subject | Esophagogastric Junction | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Stomach Neoplasms | |
dc.title | A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-11-10 | |
dc.date.updated | 2022-09-13T08:58:31Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1007/s12325-020-01567-9 | en_US |
rioxxterms.licenseref.startdate | 2020-11-26 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33244736 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1007/s12325-020-01567-9 | |
pubs.volume | 38 | |
dc.contributor.icrauthor | Chau, Ian | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectabl.pdf | |